Gustave Ronteix
Co-Founder and CTO, Orakl Oncology
Gustave Ronteix is listed as Co-Founder and CTO, Orakl Oncology. B2DB records 2 sessions at 1 conference in 2026, most recently Drug Discovery Chemistry Europe 2026 (November 2026). Speaks mainly at Hospitals and Health Care events.
Compiled from published conference agendas; not yet confirmed by Gustave. Is this you? Claim this profile.
- Sector: Hospitals and Health Care
About
Gustave Ronteix is the co-founder and Chief Technology Officer of Orakl Oncology. He has spent his career combining experimental work and computational analysis in oncology. At Orakl, he is focused on designing the combined wet lab and dry lab infrastructure that will accelerate the development of cancer therapies in the age of precision oncology. Gustave holds a PhD in quantitative biology from the Pasteur Institute and is a graduate of the Ecole polytechnique and the University of Cambridge. Gustave is the founder of the Paris chapter of Bits in Bio, hosting monthly events to animate the community at the intersection of software and biology. Thus, Gustave has both a perfect comprehension of the techbio companies at large and sharp perception of the upcoming challenges that will arise in that space.
Sessions at 1 conference
Drug Discovery Chemistry Europe 2026 11 November 2026 – 12 November 2026
- De-risking Drug Development Through Biological and Artificial Intelligence Speaker · 11 November 2026
- Panel Discussion: From Molecules to Medicines: How AI Foundation Models are Reshaping Drug Discovery Panellist · 11 November 2026
Spoke alongside
People who have shared a session with Gustave at events on B2DB.
- Fanny Jaulin CEO & Cofounder · Orakl Oncology 2 shared sessions
- Ashwini Ghogare GenAI Leader for Start-ups, Life Sciences and Healthcare · Amazon Web Services 1 shared session
- Steven Crossan CEO & Founder · Dayhoff Labs 1 shared session
- Iva Lukac Director of AI in Drug Discovery · Apheris 1 shared session
- Lindsay Edwards CTO · Relation Therapeutics Ltd. 1 shared session
- Jeremy Wohlwend CTO · Boltz 1 shared session
Others from Orakl Oncology
- Fanny Jaulin CEO & Cofounder 2 sessions